by Steve Hill – Lifespan.io –
It is thought that up to 50% of men experience hair loss as a result of pattern baldness by age 50. In this condition, the normal hair growth cycle is disrupted due to genetics, hormonal changes, and environmental factors. These things can then cause the depletion or long-term dormancy (quiescence) of hair follicle stem cells. Reviving these dormant stem cells is a potential way to treat hair loss and restart the hair growth cycle.
Building on previous clinical success
Earlier this year, Pelage Pharmaceuticals announced positive results from a phase 1 clinical trial. PP405 is a non-invasive, topical small molecule. It is also an MPC inhibitor and is based on research at UCLA that discovered a switch that can reactivate quiescent hair follicle stem cells.
